VIR BIOTECHN.INC.DL-,0001

Vir reported a net profit of $80.1 million for Q2, supported by license and collaboration revenues of $238.9 million, mainly from an upfront payment by Astellas, which raised cash and equivalents to about $1.01 billion. Phase II data for the hepatitis delta program showed an 88% “target-not-detected” rate at week 96, and recruitment for the ECLIPSE Phase III trials is complete. The stock rose more than 10% in after-hours trading; management sees financial runway into the second half of 2028 and expects top-line data from ECLIPSE 1 at the end of 2026 and from ECLIPSE 2 and 3 in early 2027. » Plus sur de.investing.com

Vir Biotechnology confirmed the resignation of CFO Jason O’Byrne; Brent Sabatini was named interim chief financial officer. O’Byrne’s exit was not due to disagreements with the company, which has already begun the search for a successor. Investors were unsettled ahead of the quarterly report on July 30, and the stock fell intraday by about 7% to $8.68. The departure follows the resignation of the chief medical officer in April and heightens concerns about leadership continuity, capital allocation and clinical priorities. » Plus sur de.investing.com

Vir Biotechnology has appointed Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin previously served as CFO of Neurocrine Biosciences and brings extensive financial and board experience, including roles as chair or member at several biopharma companies. The appointment comes during a growth phase in which Vir has more cash than debt but continues to spend on its clinical programs; the stock, the report says, was recently well above last year’s level. » Plus sur de.investing.com